Boehringer Ingelheim Signs an Exclusive Worldwide License Agreement with Oncoheroes Biosciences for Volasertib
Shots:
- Oncoheroes to get IP rights with an exclusive right to research- develop- sell and sublicense Boehringer’s Volasertib. Oncoheroes will further develop & commercialize volasertib for pediatric cancer indications
- The license agreement allows Boehringer to continue the clinical development of volasertib to benefit pediatric patients with cancer
- Volasertib is a Polo-like-kinase 1 inhibitor with strong clinical data supporting its development for rhabdomyosarcoma and a few other pediatric cancer indications. Boehringer developed Volasertib for a specific form of leukemia but it discontinued the clinical activities following the failure of P-III study in adults
Click here to read full press release/ article | Ref: PRNewswire | Image: PharmaNews
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com